The importance of neurorehabilitation to the outcome of neuromodulation in spasticity

Acta Neurochirurgica, Supplementum

Volumn , Issue 97 PART 1, 2007, Pages 243-250

  Petropoulou, Konstantina B ^a   Panourias, I G ^b   Rapidi, C A ^a   Sakas, D E ^b  

^a National Rehabilitation Center   (Greece)

^b P S Kokkalis Hellenic Center for Neurosurgical Research   (Greece)

Author keywords

baclofen; hypertonia; neuromodulation; pump; rehabilitation; Spasticity; spinal cord lesion

Indexed keywords

BACLOFEN; CENTRAL MUSCLE RELAXANT;

ELECTROSTIMULATION THERAPY; HUMAN; INFUSION PUMP; METHODOLOGY; PERIPHERAL NERVE; PHYSIOLOGY; PHYSIOTHERAPY; RADIATION EXPOSURE; REVIEW; SPASTICITY; TREATMENT OUTCOME;

BACLOFEN; ELECTRIC STIMULATION THERAPY; HUMANS; INFUSION PUMPS, IMPLANTABLE; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PERIPHERAL NERVES; PHYSICAL THERAPY MODALITIES; TREATMENT OUTCOME;

EID: 85052610181     PISSN: 00651419     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33079-1_33     Document Type: Review

References (50)

1. Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B (1996) Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow up. Arch Phys Med Rehabil 77:35-39
2. Bach-y-Rita P (1981) Central nervous system lesions: sprouting and unmasking in rehabilitation. Arch Phys Med Rehabil 62:413-417
3. Bach-y-Rita P (1981) Brain plasticity as a basis of the development of rehabilitation procedures for hemiplegia. Scand J Rehabil Med 13:73-83
4. Barnes MP, Kent RM, Semlyen JK, McMullen KM (2003) Spasticity in multiple sclerosis. Neurorehabil Neural Repair 17:66-70
5. Becker R, Alberti O, Bauer BL (1997) Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain Injury. J Neurol 224:160-166
6. Ben Smail D, Peskine A, Roche N, Mailhan L, Thiebaut I, Bussel B (2006) Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 12:101-103 (Pubitemid 43169244)
7. Bobath K, Bobath B (1984) The neuro-developmental treatment. In: Scrutton D (ed) Management of motor disorders of children with cerebral palsy. Lippencott JB, Philadelphia, pp 6-18
8. Bohannon RW, Smith MB (1987) Inter rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206-207
9. Boviatsis EJ, Kouyialis AT, Korfias S, Sakas DE (2005) Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg 107:289-295
10. Brunnstrom S (1966) Motor testing procedures in hemiplegia: based on sequential recovery stages. Phys Ther 46:357-375
11. Corry IS (1997) Botulinum toxin A in the hemiplegic upper limb:a double-blind trial. Dev Med Child Neurol 39:185-193
12. Dario A, Di Stefano MG, Grossi A, Casagrande F, Bono G (2002) Long-term intrathecal baclofen infusion in supraspinal spasticity of adulthood. Acta Neurol Scand 105:83-87
13. Dietz V, Quintern J, Berger W (1981) Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia. Brain 104:431-449
14. Dietz V, Wirz M, Curt A, Colombo G (1998) Locomotor pattern in paraplegic patients: training effects and recovery of spinal cord function. Spinal Cord 36:380-390
15. Ditunno JF, Little JW, Tessler A, Burns AS (2004) Spinal shock revisited: a four-phase model. Spinal Cord 42:383-395
16. Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71:24-26
17. Dromerick AW (2002) Clinical features of spasticity and principles of treatment. In: Gelber DA, Douglas RJ (eds) Evaluation and management of spasticity. Humana Press, Totawa, NJ, pp 13-26
18. Fehlings D, Rang M, Glazier J, Steele C (2000) An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 137:331-337
19. Francis HP, Wade DT, Turner-Stokes L, Kingswell RS, Dott CS, Coxon EA (2004) Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 75:1547-1551
20. Francisco GE, Boake C, Vaughn A (2002) Botulinum toxin treatment of upper extremity spasticity secondary to acquired brain injury: a randomized trial comparing two commonly used dilution techniques. Am J Phys Med Rehabil 8:355-363
21. Francisco GE, Hu MM, Boake C, Ivanhoe CB (2005) Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Inj 19:359-364
22. Francois B, Vacher P, Roustan J, Salle JY, Vidal J, Moreau JJ, Vignon P (2001) Intrathecal baclofen after traumatic brain injury: early treatment using a new technique to prevent spasticity. J Trauma 50:158-161
23. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM (1997) Traditional pharmacological treatments for spacticity part II: general and regional treatments. Muscle Nerve Suppl 6: S92-S120 (Pubitemid 128753040)
24. Gracies JM, Fitzpatrick R, Wilson L, Burke D, Gandevia SC (1997) Lycra garments designed for patients with upper limb spasticity: mechanical effects in normal subjects. Arch Phys Med Rehabil 78:1066-1071
25. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM (1997) Traditional pharmacological treatments for spacticity part I: local treatments. Muscle Nerve Suppl 6: S1-S92
26. Hallenborg SC (1990) Positioning in the practical management of spasticity. In: Glenn MB, Whyte J (eds) Children and adults. Lea and Febinger, Philadelphia, pp 97-117
27. Hesse S, Werner C, von Frankenberg S, Bardeleben A (2003) Treadmill training with partial body weight support after stroke. Phys Med Rehabil Clin N Am 14 Suppl 1: S111-S123
28. Kabus C, Hecht M, Japp G, Jost WH, Pohlau D, Stuckrad-Barre S, Winterholler M (2006) Botulinum toxin in patients with multiple sclerosis. J Neurol 253 Suppl 1: i26-i28
29. Kagaya H, Yamada S, Nagasawa T, Iashihara Y, Kodama H, Endoh H (1996) Split posterior tibial tendon transfer for various deformity of the hind-foot. Clin Orthop Rel Res 323:254-260
30. Keenan MAE, McDaid PJ (2002) Orthopedic interventions for the management of limb deformities in upper motoneuron syndromes. In: Gelber DA, Jeffrey DR (eds) Clinical evaluation and management of spasticity. Humana Press, Totowa, NJ, pp 197-255
31. Ko HY, Ditunno JF, Graziani V, Little JW (1999) The pattern of reflex recovery during spinal shock. Spinal Cord 37:402-409
32. Kraft GH, Fitts SS, Hammond MC (1992) Techniques to improve function of the hand and arm in chronic hemiplegia. Arch Phys Med Rehabil 73:220-227
33. Kunkel A, Kopp B, Muller G, Villringer K, Villringer A, Taub E, Flor H (1999) Constraint-induced movement therapy. A powerful new technique to induce motor recovery in chronic stroke patients. Arch Phys Med Rehabil 80:624-628
34. Lieber RL, Jan Fride N (2002) Spasticity causes a fundamental rearrangement of muscle-joint interaction. Muscle Nerve 25:265-270
35. Mayer NH (1997) Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 6: S1-S13
36. Meythaler JM (2002) Pharmacology update: intrathecal baclofen for spastic hypertonia in brain injury. J Head Trauma Rehabil 12:87-90
37. Nancy B, Jennifer R, Olfat M, Monica H, Josh K, Amy S, Molly T, Gary A (2003) Effectiveness of sensory and motor rehabilitation of the upper limb following the principles of neuroplasticity: patients stable poststroke. Neurorehabil Neural Repair 17:176-191
38. Nudo RJ, Wise BM, Si Fuentes F, Milliken GW (1996) Neural substrates for the effects of rehabilitation training on motor recovery after ischemic infarct. Science 272:1791-1794
39. Petropoulou K, Rapidi A-C, Noussias V, Berbatiotou L (2001) Study of the effectiveness of botulinum toxin type A in hemiplegic arm spasticity. Neurorehab Neural Repair 15:323 (abstract)
40. Pierson SH (2002) Physical and occupational approaches. In: Gelber DA, Jeffery DR (eds) Clinical evaluation and management of spasticity. Humana Press, Totawa, NJ, pp 47-66
41. Seeberger LC, O'Brien CF (2002) Botulinum toxins. In: Gelber DA, Jeffery DR (eds) Clinical evaluation and management of spasticity. Humana Press, Totawa, NJ, pp 173-186
42. Simpson DM (1997) Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl 6: S169-S175
43. Smeulders MJC, Kreulen M, Huijing JHPA, van der Horst CM (2005) Spastic muscle properties are affected by length changes of adjacent structures. Muscle Nerve 32:208-215
44. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28:512-515
45. Stokic DS, Yablon SA, Hayes A (2005) Comparison of clinical and neurophysiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury. Arch Phys Med Rehabil 86:1801-1806
46. Taub E, Burgio L, Miller NE, Cook EW III, Groomes T, De Luca S, Crago J (1994) An operant approach to overcoming learned nonuse after CNS damage in monkeys and man: the role of shaping. J Exp Anal Behav 61:281-293
47. Tilton AH (2003) Approach to the rehabilitation of spasticity and neuromuscular disorders in children. Neurol Clin 21:853-881
48. Tizard JP (1980) Cerebral palsies: treatment and prevention. The Croonian lecture 1978. J R Coll Physicians 14:72-77
49. Zafonte R, Lombard L, Elovic E (2004) Antispasticity medications: uses and limitations of enteral therapy. Am J Phys Med Rehabil 83: S50-S58
50. Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS (2004) Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 75:1553-1557